Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this entry is available only to subscribers.
"Antiplatelet Drugs for Prevention of Restenosis After Peripheral Endovascular Treatment." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/455589/all/Antiplatelet_drugs_for_prevention_of_restenosis_after_peripheral_endovascular_treatment.
Antiplatelet drugs for prevention of restenosis after peripheral endovascular treatment. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/455589/all/Antiplatelet_drugs_for_prevention_of_restenosis_after_peripheral_endovascular_treatment. Accessed July 16, 2020.
Antiplatelet drugs for prevention of restenosis after peripheral endovascular treatment. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. Retrieved July 16, 2020, from https://evidence.unboundmedicine.com/evidence/view/EBMG/455589/all/Antiplatelet_drugs_for_prevention_of_restenosis_after_peripheral_endovascular_treatment
Antiplatelet Drugs for Prevention of Restenosis After Peripheral Endovascular Treatment [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2020 July 16]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/455589/all/Antiplatelet_drugs_for_prevention_of_restenosis_after_peripheral_endovascular_treatment.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Antiplatelet drugs for prevention of restenosis after peripheral endovascular treatment
ID - 455589
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/455589/all/Antiplatelet_drugs_for_prevention_of_restenosis_after_peripheral_endovascular_treatment
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
Try the app for free!
1. Download the Evidence Central web app app by Unbound Medicine
2. Select Try/Buy and follow instructions to begin your free 30-day trial
You can cancel anytime within the 30-day trial, or continue using Evidence Central web app
to begin a 1-year subscription ($39.95)
Want to read the entire topic?
Access up-to-date medical information for less than $2 a week